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Optimal treatment for obsessive compulsive disorder:
a randomized controlled feasibility study of the
clinical-effectiveness and cost-effectiveness of
cognitive-behavioural therapy, selective serotonin reuptake
inhibitors and their combination in the management of
obsessive compulsive disorder
Naomi A. Fineberga,b,c, David S. Baldwind,e, Lynne M. Drummondf,g,
Solange Wyattb, Jasmine Hansona, Srinivas Gopia, Sukhwinder Kaura,
Jemma Reida,b, Virender Marwaha, Ricky A. Sachdeva, Ilenia Pampalonif,
Sonia Shahpera, Yana Varlakovaa, Davis Mpavaendaa, Christopher Mansond,
Cliodhna O’Learyd, Karen Irvinea,b, Deela Monji-Patela, Ayotunde Shodunkea,
Tony Dyerh, Amy Dymondh, Garry Bartonh and David Wellstedb
Established treatments for obsessive compulsive disorder
(OCD) include cognitive behaviour therapy (CBT) and
selective serotonin reuptake inhibitor (SSRI) medication.
Combined treatment may outperform monotherapy, but few
studies have investigated this. A total of 49 community-
based adults with OCD were randomly assigned to CBT,
SSRI, or SSRI+CBT. Sertraline (50–200mg/day) was given
as the SSRI for 52 weeks. A 16-h-manualized individual
CBT was delivered over 8 weeks with four follow-up
sessions. Assessors were ‘blinded’ to treatment allocation.
A preliminary health economic evaluation was conducted. At
week 16, combined treatment (n= 13) was associated with
the largest improvement, sertraline (n= 7) the next largest
and CBT (n= 9) the smallest on the observed case analysis.
The effect size (Cohen’s d) comparing the improvement in
Yale Brown Obsessive Compulsive Scale on CBT versus
combined treatment was − 0.39 and versus sertraline was
− 0.27. Between 16 and 52 weeks, the greatest clinical
improvement was seen with sertraline, but participant
discontinuation prevented reliable analysis. Compared with
sertraline, the mean costs were higher for CBT and for
combined treatment. The mean Quality Adjusted Life Year
scores for sertraline were 0.1823 (95% confidence interval:
0.0447–0.3199) greater than for CBT and 0.1135 (95%
confidence interval: ‑ 0.0290– 0.2560), greater than for
combined treatment. Combined treatment appeared the
most clinically effective option, especially over CBT, but the
advantages over SSRI monotherapy were not sustained
beyond 16 weeks. SSRI monotherapy was the most cost-
effective. A definitive study can and should be
conducted. Int Clin Psychopharmacol 00:000–000 Copyright
© 2018 The Author(s). Published by Wolters Kluwer Health,
Inc.
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Background
Obsessive compulsive disorder (OCD) is a common,
disabling, relapsing psychiatric illness (Skoog and Skoog,
1999). Combining pharmacotherapy with cognitive
behaviour therapy (CBT) has been considered superior
to either treatment given alone, but is probably more
costly, and few controlled studies have addressed this
question (Fineberg et al., 2013). Moreover, interpretation
of the many published studies is compromised by poor
study design (Skapinakis et al., 2016a, 2016c). UK NICE
guidelines (National Institute for Health and Care
Excellence, 2006) recommend monotherapy with either
CBT [including exposure and response prevention
(ERP)] or selective serotonin reuptake inhibitor (SSRI)
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medication as standard first-line treatments, with com-
bined therapy (CBT+SSRI) reserved for patients with
more severe or enduring illness. This staging is, however,
largely based on clinical consensus (level IV evidence).
There is additional uncertainty relating to the quality of
life (QOL) gain and cost-effectiveness associated with
the different treatment options (National Institute for
Health and Care Excellence, 2006; Skapinakis et al.,
2016b).
Robust data from randomized controlled studies (RCTs)
in OCD suggest that continuing an SSRI protects against
relapse (Fineberg et al., 2007), whereas discontinuation
contributes to relapse and reduction in life quality
(Hollander et al., 2010). Continuation-treatment with
SSRI is, therefore, a recognized strategy for long-term
well-being (Fineberg et al., 2015). In contrast, little is
known from RCTs about long-term outcomes of OCD
following the termination of a course of CBT. There
remains a need for studies to determine the effectiveness
of CBT ‘booster-regimes’ as an alternative means to
prevent relapse (Fineberg et al., 2013). Taking this
uncertainty into consideration, there is a pressing need
for RCTs of combined treatment versus monotherapy of
adequate duration to meaningfully guide optimal service
delivery for people with OCD.
Aims and objectives
This 52-week feasibility study was designed to inform
the design of a definitive RCT, to determine the clinical-
effectiveness and cost-effectiveness of combining CBT
with SSRI versus either treatment when given alone, in
patients not known to be treatment resistant. We,
therefore, included a broad range of outcomes covering
several modalities including the number of eligible
patients randomized, clinical outcomes, premature dis-
continuation rates, tolerability across treatment arms,
resource use and QOL.
A key objective was to estimate the relative effect size of
each arm, for which we used an observed case analysis of
the variation in the primary endpoint – defined as the
change in total Yale Brown Obsessive Compulsive Scale
(Y-BOCS; Goodman et al., 1989) score, both within and
between the three treatment arms at week 16 and
beyond, in order to estimate the sample size required to
power a definitive trial.
Methods and analysis
The trial was approved by the East of England NHS
ethics committee, REC reference 13/EE/0431. Written
informed consent was obtained from all participants, both
for screening and for the treatment phase. The trial
strictly followed Good Clinical Practice regulations.
Design
This was a three-arm, multicentre, randomized, feasi-
bility trial. The treatment arms were SSRI monotherapy,
CBT monotherapy, and the combination of SSRI and
CBT. The trial assessed adult participants (18–65 years)
over 52 weeks with measures taken at weeks 0, 2, 4, 8, 16,
32 and 52. To minimize bias, the outcome assessments
were performed by researchers who were separate from
the clinical teams and blinded to treatment allocation.
Location
The study took place at three UK centres accessing large
populations of OCD patients: Hertfordshire Partnership
University NHS Foundation Trust; South West London
and St George’s NHS Mental Health Trust and Southern
Health NHS Foundation Trust. Depending on local
service configuration, aspects of study treatment for
patients with moderate-intensity OCD were delivered in
the primary care (immediate access to psychological
therapies) setting to model usual practice.
Participant selection
Participants were male or female treatment-seeking
community-based patients aged 18–65 years with an
OCD of at least moderate severity and a documented
duration of symptoms greater than one year taken from
their medical records. They were identified from routine
trust referrals, active recruitment from usual referral
sources including primary healthcare services [e.g. gen-
eral practitioners (GPs), immediate access to psycholo-
gical therapies services], community mental health
clinics, psychotherapy waiting lists and advertisement
through national OCD and other charities, as well as
through local media adverts including websites, news-
papers and radio programmes.
Inclusion
Participants needed to have a Diagnostic and Statistical
Manual of Mental Disorders, 4th ed. (DSM-IV) diagnosis of
OCD (American Psychiatric Association, 1994), deter-
mined by a doctor using the Mini International
Neuropsychiatric Inventory for DSM-IV (Sheehan et al.,
1998) and a baseline total score of more than 16 on the
Y-BOCS. Participants with comorbid psychiatric dis-
orders were allowed to enter the study, subject to the
exclusion criteria listed below, and provided OCD was
judged to be the primary focus of clinical intervention.
Exclusion
Those with a history of psychotic disorder, Tourette syn-
drome (tic disorders not amounting to Tourette syndrome
were allowed), organic mental disorder, psychosurgery,
personality disorder of borderline or histrionic type, or
alcohol/substance-abuse disorders within the past 12 months
were not recruited. In addition, those with severe depressive
symptoms, defined by a Montgomery–Asberg Depression
Rating Scale (MADRS; Montgomery and Åsberg, 1979)
score of more than 30 at baseline, or those actively planning
suicide (scoring >4 on item 10 of MADRS), or judged by
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the clinician to be at significant risk of self-harm, were
excluded.
We also excluded individuals with treatment-resistant
OCD, defined as failing to respond to more than one pre-
vious adequate (>12 weeks) trial of CBT involving ERP
from an accredited (British Association of Behavioural and
Cognitive Psychotherapies approved or equivalent) thera-
pist, or failing to respond to more than 2 adequate
(>12 weeks) trials of any SSRI or clomipramine taken at
optimal doses (if <maximum SPC dose, evidence of
intolerance of the higher dose was needed) with adequate
adherence.
Those needing regular psychotropic drugs other than
study medication during the trial (except for hypnotics,
which were allowed, provided the dose had been stable
for at least 12 weeks, and remained so throughout the
study period), or needing regular specified medication
that might interact adversely with sertraline were also
excluded, as were those with acute or unstable physical
illness, women of child-bearing age who were not using
reliable contraceptive methods, those who for individual
reasons would find it difficult to comply with the treat-
ment programme, including the washout period, and
those who were judged to have insufficient under-
standing of English to participate in treatment or provide
informed consent.
Screening
Interested individuals were given a brief explanation of
the trial, and a preliminary assessment of eligibility was
undertaken. Potentially eligible and willing participants
were provided with a patient information sheet and an
appointment for a screening visit, being allowed at least
24 h for further consideration. At the screening visit, the
patient was fully assessed by members of the research
team, including a psychiatrically qualified research doctor
who confirmed eligibility, on the basis of the inclusion
and exclusion criteria, and obtained written consent.
Depending upon the medical history, the need for a
‘washout period’ was ascertained. Those not needing
washout were randomized, and baseline assessments
were made during this visit. For those requiring a ‘wash-
out’, the previous medication was discontinued according
to standard guidance: individuals were then reassessed
after a drug-free period, normally lasting one week (in the
case of fluoxetine, 6 weeks).
Clinical contact was maintained throughout.
Randomization
An independent online randomization service was pro-
vided by the Norwich Clinical Trials Unit (University of
East Anglia). Participants were randomized to one of the
treatment arms in a ratio of 1 : 1 : 1, and the patient was
informed of the allocated treatment. Patients were spe-
cifically asked not to discuss their treatment allocation
with the ‘blinded’ research assistant who conducted the
subsequent ratings. They were provided with 24-h clin-
ical contact information.
Interventions
Participants were randomized to one of three interven-
tions, designed to approximate to normal UK-prescribing
and CBT practice:
(1) Sertraline (50–200 mg) (group 1): 30-min outpatient
visits with the doctor took place at weeks 0, 2, 4, 8,
16, 24, 32 and 52, at which sertraline was prescribed,
and the effects, adverse events (AEs) and dosage
were reviewed. From week 0, sertraline was flexibly
titrated upwards from 50 to 200 mg, in accordance
with the licence, and guided by tolerability and
clinician-patient judgement. Doses could be adjusted
upwards or downwards for the first 8 weeks, aiming
for the highest tolerated dose, after which the dosage
of medication was fixed until week 52. No CBT was
provided, and doctors were trained to avoid covert
discussion of CBT exercises.
(2) CBT with ERP (group 2): CBT incorporated cognitive
and behavioural interventions, including graded ERP,
with individual face-to-face contact and homework
assignments, as recommended by National Institute
for Health and Care Excellence (2006). Treatment was
manualized and adapted from Steketee (1993). In
accordance with NICE guidance and with the level of
illness severity of the OCD patients (Y-BOCS>16; not
treatment resistant), a moderate-intensity CBT package
was offered, comprising eight sessions of individual
treatment, each lasting 2 h, to be delivered over 8 weeks.
Four 1-h follow-up sessions were provided at weeks 16,
24, 32 and 52.
(3) All CBT therapists were accredited by the
British Association of Behavioural and Cognitive
Psychotherapies or an equivalent professional body.
Therapists received refresher training in CBT with
ERP and training in the manual from one of the
principal investigators with special expertise in
CBT and ERP (L.D.). Therapists underwent peer
group supervision on a regular basis. In addition, a
sample of CBT sessions were audiotaped for
fidelity, which was assessed for quality by L.D.
(4) Sertraline (50–200 mg) plus CBT with ERP (group
3): Participants received both sertraline and CBT as
per groups one and two.
At each study visit, patients were encouraged to return
any unused medication, and a pill count was performed.
For patients receiving CBT, information on attendance at
scheduled therapy sessions, length of sessions and com-
pletion of homework was recorded.
At the end of study treatment, patients were referred to
differing services, depending on their clinical status. In
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the case of premature discontinuation, patients were
invited to continue with study assessments by the
research assistant for research assessments until week 52,
for research purposes only.
Outcomes and endpoints
Randomized participants were evaluated at weeks 0, 2, 4,
8, 16, 32 and 52 by research assistants who were blinded to
the treatment allocation. Every attempt was made to pre-
serve rater blindness. The following outcomes were
evaluated:
(1) Primary outcomes: variation of the Y-BOCS as the
primary outcome measure, both within and between
the treatment arms, at week 16 (primary endpoint)
and at week 52 (final endpoint).
(2) Secondary outcomes: variation of the following out-
comes on patient selection and on the primary
endpoint, to inform minimization strategies in the
subsequent definitive trial, and the need for adjusted
and stratified analysis.
(a) CGI Severity Scale and CGI Improvement Scale
(Guy, 1976).
(b) Sheehan Disability Scale (SDS) (Sheehan et al.,
1996).
(c) MADRS (Montgomery and Åsberg, 1979).
(d) Autism quotient (Baron-Cohen et al., 2001) and
performance on a computerized neurocognitive
battery– to be reported separately.
(3) At weeks 0, 16 and 52, the self-report EuroQoL EQ-
5D-3L (Brooks, 1996) was administered. Treatment
costs were assessed from an NHS and personal social
services (PSS) perspective using an adapted version
of the Client Service Receipt Inventory (Beecham
and Knapp, 1992).
(4) Treatment-related adverse effects were measured via
direct interview and grouped according to MeDRA
terminology (Brown et al., 1999). Tolerability measures
including dropout rates and reasons were recorded.
Every effort was made to assess patients on the exact
scheduled day; however, assessments could be made
± 3 days outside this.
Sample size calculation
Cocks and Torgerson (2013) recommend estimating the
required sample size for a feasibility study based on a
one-sided 80% confidence interval (CI) designed to
exclude the minimum difference of clinical interest in
the primary outcome measure. For the Y-BOCS, we
estimated a typical pooled SD to be 8, giving an effect
size of 0.25 for a two-point change and an effect size of
0.375 for a three-point change, equating to a required
sample size of 251/arm. Cocks and Torgerson (2013) also
recommend the sample size for a pilot study to amount to
9% of the estimated sample size. Thus, the range of
required sample size was between 10 and 22 patients/
arm, given the range of the expected effect. The sample
size for this study was, therefore, set at 20/arm, assuming
a total of 60 participants randomized and 45 patients
completing the trial at least to 16 weeks, which we
defined as the primary endpoint, to provide a robust
estimate excluding a minimum change of three points in
the worst case.
Analysis
OTO was designed as a feasibility study, with the aim of
ascertaining the relative effect sizes associated with the
different treatment arms using observed cases, repre-
senting the most sensitive analysis, as it involves the
fewest statistical assumptions. We also conducted sensi-
tivity analyses of the ‘intent to treat’ (ITT) population to
examine the extent to which the observed case findings
could be confirmed, although the small sample size
compromized the robustness of these additional analyses.
The ITT analysis was evaluated as a mixed model with
unstructured variance and appropriate interaction terms.
Economic evaluation
The health economics component sought to measure the
level of participant resource use and QOL within each of
the three treatment options (sertraline, CBT and sertra-
line plus CBT).
All costs were estimated for the 2015/2016 financial year,
from an NHS and PSS cost perspective. In terms of
intervention costs, sertraline appointments were made with
a specialist psychiatric registrar, who recorded attendance
and sertraline dosage prescribed. Appointments were
assumed to last 30min, with an additional 30min of non-
contact time and 5min of supervision (with a consultant
psychiatrist), per appointment. CBT therapists recorded
attendance and the contact time of each session. In addi-
tion, we assumed that there was 1 h extra of noncontact
staff time per session, and that two CBT therapists per site
received 2 h of joint CBT training, and 1 h supervision per
month, from a consultant psychiatrist. However, research
costs, for example, the time associated with the completion
of outcome measures, were not included, as these would
not be incurred if this intervention was provided in
the NHS.
At baseline and subsequent in-person follow-up visits (16
and 52 weeks), participants were asked whether they had
received any of a selection of other healthcare-related
services (over a common time period of the previous
16 weeks), and to list the associated level of resource use
(if applicable).
Unit costs (Table 1) were assigned to all items of resource
use, and these costs were then summed in order to
estimate the total per participant cost, wherein the total
cost of both CBT training and supervision was equally
apportioned across all those allocated to a CBT option.
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QOL was measured using the EQ-5D-3L (Brooks, 1996)
at baseline, 16 and 52 weeks. Responses were converted
into utility scores (a scale wherein 0 is equal to death and
1 is full health) (Drummond et al., 2015) using the York
A1 tariff (Dolan, 1997), and Quality Adjusted Life Year
(QALY) scores were subsequently calculated for the
52-week follow-up period, using the total area under the
curve approach (Manca et al., 2005).
Analysis included the estimation of completion rates and
large cost drivers to inform the decision as to how costs
and benefit should be collected as part of any future
definitive study. A preliminary within-trial assessment of
cost-effectiveness was also conducted (no discounting
was undertaken, as time period was 1 year), on the basis
of a complete-case approach (Briggs et al., 2003), whereby
participants were only included if the annual overall cost
(the average cost of the first and last 16 weeks was used
to estimate levels of resource use between weeks 16 and
36) and QALY score could be estimated. A bivariate
regression (Willan et al., 2004) was then undertaken to
estimate the mean difference in overall cost and mean
difference in QALYs between each of the three different
treatment options. Cost and effect regression analyses
were run simultaneously, with age, sex, ethnicity, marital
status, living situation and education included as covari-
ates, as well as the baseline EQ-5D score for the QALY
regression. To estimate which option constituted ‘best
value for money’, dominated options were ruled out on
the basis that another option had both a higher mean
effect and a lower mean cost. The incremental cost-
effectiveness ratio (Drummond et al., 2015) (mean
incremental cost/mean incremental effect) was subse-
quently estimated for the remaining options, wherein an
incremental cost-effectiveness ratio below £20 000 was
considered to constitute value for money (Briggs et al.,
2002; National Institute for Health and Clinical
Excellence, 2008). To estimate the associated level of
uncertainty, the cost-effectiveness acceptability curve,
which depicts the probability of an intervention being
cost-effective at various ‘willingness to pay’ thresholds
(Briggs et al., 2002), was also estimated.
Results
Recruitment
A total of 258 patients were assessed for eligibility, of
whom 59 were excluded and 150 declined to participate
(Fig. 1). A total of 66 patients were screened, 10 were
excluded and seven withdrew before randomization.
Table 1 Estimated unit costs, with associated sources
Sertraline Unit cost
Appointment with specialist registrar £71.84 (Pay and Conditions Circular M&D, 2016)
Supervision (5 min/appointment) £14.88 (Pay and Conditions Circular M&D, 2016; Health and Social Care Information Centre, 2016)
Medication monthly prescription (50 mg)a £2.47 (National Health Service Business Authority, 2017)
Medication monthly prescription (100 mg)a £2.52 (National Health Service Business Authority, 2017)
Medication monthly prescription (150 mg)a £3.97 (National Health Service Business Authority, 2017)
Medication monthly prescription (200 mg)a £4.03 (National Health Service Business Authority, 2017)
Unit cost
CBT Therapist (band 7) (Curtis and Burns, 2016) Trainer (band 9)
Therapist (cost/h of employment) £52.79 £106.71
Unit cost (Curtis and Burns, 2016)
Health professional contacts (cost/visit) GP clinic Homeb Hospital
Counsellor/therapist £50.58 £62.54 £51.98
Mental health nurse £68.04 £78.71 £66.15
Psychologist £65.00 £78.87 £67.50
Psychiatrist £150.24 £193.41 £168.60
Nurse (at GP surgery) £12.12 – –
GP £31.00 £63.44 £135.27
Physiotherapist £26.72 £65.23 £48.33
Occupational therapist £41.83 £84.66 £65.85
Speech therapist £26.72 £65.23 £27.36
Social worker £40.45 £50.01 £41.57
GP phone call £11.85
Nurse phone call £6.30
Hospital admissions (cost/bed day) £395.33 (Department of Health, 2016)
Accident and emergency (cost/visit) £96.25 (Department of Health, 2016)
Other outpatient visit (cost/visit) £116.92 (Department of Health, 2016)
Day case procedure (cost/procedure) £398.02 (Department of Health, 2016)
CBT, cognitive-behavioural therapy; GP, general practitioner.
aThis includes an additional per prescription packaging cost of £1.01 and a pharmacist fee of £0.90.
bIncludes estimated travel cost.
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Fig. 1
Combined Sertraline CBT
¨
¨
Allocated to intervention (n=18)
Received (n=15)
Not received (n=3)
¨
¨
Allocated to intervention (n=15)
Received (n=14)
Not received (n=1)
¨
¨
Allocated to intervention (n=16)
Received (n=15)
Not received (n=1)
8 Week Follow-Up
Lost to follow-up (n=0)
Discontinued intervention2 (n=3)
Withdrew from study (n=3)
Other (n=1)
Analysed (n=14)
Lost to follow-up (n=1)
Discontinued intervention2 (n=0)
Withdrew from study (n=3)
Other (n=2)
Analysed (n=9)
Lost to follow-up (n=0)
Discontinued intervention2 (n=4)
Withdrew from study (n=4)
Other (n=1)
Analysed (n=13)
Lost to follow-up (n=1)
Discontinued intervention2 (n=0)
Withdrew from study (n=4)
Other (n=3)
Analysed (n=7)
Lost to follow-up (n=0)
Discontinued intervention2 (n=4)
Withdrew from study (n=9)
Other (n=1)
Analysed (n=8)
Lost to follow-up (n=3)
Discontinued intervention2 (n=0)
Withdrew from study (n=6)
Other (n=0)
Analysed (n=6)
Lost to follow-up (n=0)
Discontinued intervention2 (n=4)
Withdrew from study (n=9)
Other (n=0)
Analysed (n=9)
Lost to follow-up (n=3)
Discontinued intervention2 (n=0)
Withdrew from study (n=6)
Other (n=0)
Analysed (n=6)
Lost to follow-up (n=4)
Discontinued intervention2 (n=5)
Withdrew from study (n=4)
Other (n=0)
Analysed (n=8)
Lost to follow-up (n=3)
Discontinued intervention2 (n=4)
Withdrew from study (n=4)
Other (n=1)
Analysed (n=8)
Lost to follow-up (n=1)
Discontinued intervention2 (n=3)
Withdrew from study (n=3)
Other (n=3)
Analysed (n=9)
Lost to follow-up (n=0)
Discontinued intervention2 (n=0)
Withdrew from study (n=1)
Other (n=3)
Analysed (n=12)
16 Week Follow-Up
32 Week Follow-Up
52 Week Follow-Up
Analysis
Analysed (n=9)
Excluded from analysis (n=9)
Analysed (n=8)
Excluded from analysis (n=8)
Analysed (n=6)
Excluded from analysis (n=9)
Enrollment
Assessed for eligibility1 (n=258)
Excluded (n=209)
¨ Not meeting inclusion criteria (n=59)
¨ Declined to participate (n=150)
¨ Other reasons (n=0)
Allocation
Randomised (n=49)
Study flow chart. 1Total N is defined as all unique patient identifiers on the study database. 2Patients withdrew from treatment, but agreed to be
followed-up. 3Other is defined as patients who did not attend assessment at that time point.
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A total of 49 patients were randomized (Hertfordshire
Partnership University NHS Foundation Trust: 24;
South West London and St George’s NHS Mental
Health Trust: 8; Southern Health NHS Foundation
Trust: 17), of whom 28 were female individuals. The
major referral source for these patients was secondary
care psychiatric services (n= 21).
Baseline characteristics
The three groups were reasonably well matched at
baseline (Table 2). Overall, there was a slight pre-
ponderance of female individuals, and most patients were
educated at least to university degree level. The mean
total Y-BOCS score of 26.7 (SD: 7.5) indicated moder-
ately severe OCD. Comorbid depression was diagnosed
in 14 patients, although the mean total MADRS score of
16.1 (SD: 10.1) indicated that the severity of depression
was not high in most cases. As expected, the most
common psychiatric comorbidity was anxiety disorder
(n= 28). Also present were hoarding disorder (n= 7),
body dysmorphic disorder (n= 5), obsessive–compulsive
personality disorder (n= 3), skin-picking disorder (n= 2),
hair-pulling disorder (n= 2) and eating disorder (n= 1).
Patients were moderately impaired on the SDS, con-
sistent with the community-based nature of the sample.
However, the majority were single or divorced (39/49),
consistent with the high celibacy rates seen in OCD.
Acceptability
Five patients did not start the allocated study therapy
after randomization: one CBT and one sertraline and
three combined (one combined patient completed
CBT only). Two patients cited not wanting the allocated
treatment, and one not wanting to undergo washout, as
their reasons for nonparticipation.
Delay to starting treatment
There was on average an ~ 4-week delay in starting CBT,
owing to logistical constraints; hence, most participants
completed CBT between week 8 and week 16.
Retention
Of the 44 participants starting treatment, 35 (79.6%) com-
pleted 8 weeks on the study and 29 (65.9%) reached the
week 16 endpoint (CBT= 9, SSRI= 7, CBT+SSRI= 13).
Only two of the 15 participants who received their allo-
cated treatment and discontinued the study within the first
16 weeks were receiving CBT+SSRI, compared with six
receiving CBT and seven receiving SSRI, suggesting a
possible advantage in terms of retention for the combined
treatment group during the acute treatment phase.
However, the number of patients completing 16 weeks
fell short of the study power set in the protocol, for which
we required 15 patients to complete each study arm
(or 45 in all).
Table 2 Baseline patient characteristics
Characteristics n (%) HPFT SWLSTG STSN Sertraline CBT Combined
N 49 (100) 24 (49) 8 (16) 17 (35) 15 (31) 16 (33) 18 (36)
Male 21 (43) 11 (46) 4 (50) 6 (35) 8 (53) 6 (38) 7 (39)
Female 28 (57) 13 (54) 4 (50) 11 (65) 7 (47) 10 (62) 11 (61)
Ethnicity
White 43 (88) 22 (92) 7 (88) 14 (82) 12 (80) 15 (94) 16 (89)
Black 1 (2) – – 1 (6) 1 (6) – –
Oriental 1 (2) – 1 (12) – 1 (6) – –
Asian 1 (2) – – 1 (6) – – 1 (6)
Other 3 (6) 2 (8) – 1 (6) 1 (7) 1 (6) 1 (6)
Living status
Divorced 3 (6) 1 (4) – 2 (12) 1 (7) 2 (13) –
Partnership 10 (20) 5 (21) 2 (25) 3 (18) 4 (27) 2 (13) 4 (22)
Single 36 (73) 18 (75) 6 (75) 12 (71) 10 (66) 12 (75) 14 (78)
Living situation
Alone 8 (16) 3 (13) 1 (13) 4 (24) 2 (12) 2 (11) 4 (27)
Residence 2 (4) – – 2 (12) – 1 (6) 1 (7)
Family 22 (45) 11 (46) 4 (50) 7 (42) 10 (63) 10 (56) 2 (13)
Friends 2 (4) – 1 (13) 1 (6) 1 (6) – 1 (7)
Partner 15 (31) 10 (42) 2 (25) 3 (18) 3 (19) 5 (28) 7 (47)
Education
None 5 (10) 1 (4) – 4 (24) 2 (11) 2 (13) 2 (11)
GCSE or A
level
16 (33) 9 (37) 2 (25) 5 (29) 7 (38) 4 (25) 7 (29)
Degree 23 (47) 9 (37) 6 (75) 8 (46) 7 (38) 10 (62) 6 (40)
Postgraduate 5 (10) 5 (21) – – 2 (11) – 2 (11)
Y-BOCS 44 22 8 14 13 14 17
26.8 (5.3) 27.4 (4.5) 25.5 (5.4) 26.9 (6.6) 26.5 (4.5) 27.1 (5.8) 26.9 (5.7)
MADRS 45 22 8 15 14 14 17
14.8 (8.1) 12.7 (5.3) 10.9 (7.3) 20.0 (9.7) 13.4 (8.0) 13.7 (8.7) 16.8 (7.8)
Autism quotient 47 23 7 17 15 15 17
21.7 (6.0) 20.8 (6.5) 20.4 (4.2) 23.5 (5.6) 22.4 (5.5) 21.0 (6.1) 21.8 (6.5)
CBT, cognitive-behavioural therapy; HPFT, Hertfordshire Partnership University NHS Foundation Trust; MADRS, Montgomery Asberg Depression Rating Scale; SHFT,
Southern Health NHS Foundation Trust; SWLSTG, South West London and St George’s NHS Mental Health Trust; Y-BOCS, Yale Brown Obsessive Compulsive Scale.
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Between 16 and 52 weeks, only a further six patients dis-
continued. At 52 weeks, 23 (52.3%) participants remained in
the study (CBT=8, SSRI=6, CBT+SSRI=9).
Reasons for discontinuation
Reasons for premature withdrawal were obtained in 19 of
the 26 cases, of which seven appeared directly related to
study procedures. Four participants found randomization
to SSRI unacceptable, one found washout of SSRI
unacceptable, and two found attendance at study
assessments unacceptable.
Adherence
The majority of patients on SSRI [29/33 (88%)] took
study medication as prescribed, as measured by pill
counts on returned packets. The mean daily dose of
sertraline prescribed in the SSRI group at week 52 was
166.67 mg, and, in the combination group, it was
100.00 mg.
Adherence to CBT was also found to be acceptable,
according to a predetermined criterion of 75% com-
pliance, in 24 (71%) of the 34 cases. For those patients
who did not withdraw prematurely, almost all study
assessments were completed. Fidelity to CBT was con-
firmed by random sampling of audiotaped sessions and
assessment by a CBT expert (L.D.).
Two patients randomized to combination therapy and
one patient randomized to SSRI monotherapy took no
study medication (100% noncompliant), as they did not
want to take medication. One patient randomized to
combination therapy stopped study medication but con-
tinued to take a lower dose of sertraline prescribed by
their GP. Four patients in the CBT arm started medi-
cation [three sertraline (2 at week 8, 1 at week 16), 1
fluoxetine at week 24] while still on study treatment.
Clinical outcomes
Primary outcome (Y-BOCS)
All treatment arms were associated with a numerical
improvement in total Y-BOCS scores over the course of
the 52-week study (Table 3). At week 16 (primary end-
point), there was a substantial advantage for the combi-
nation treatment over CBT (Cohen’s d= 0.39, 95% CI:
− 0.47 to 1.24) and a more modest advantage for SSRI
over CBT (d= 0.27, 95% CI: − 0.73 to 1.3). At week 32
and at week 52, however, there was a marked advantage
for SSRI monotherapy when compared with both CBT
[d (week 32)= 0.57, 95% CI: − 0.52 to 1.7; d (week
52)= 0.56, 95% CI: − 0.53 to 1.6] and combination
treatment [d (week 32)=− 0.49, CI: − 1.6 to 0.59; d
(week 52)=− 0.44, 95% CI: − 1.5 to 0.61] (Table 3).
Intent-to-treat analysis for the primary outcome
The findings of the ITT analysis are shown in Tables 3,
5 and 6, showing the difference between the arms as an
adjusted difference. While the adjusted group
differences do vary from the observed difference (in the
middle section in each table), the overall pattern of the
outcome is very similar to the observed group differ-
ences, and no change in the interpretation of the data is
necessary. The largest change is seen for the MADRS in
the comparison between CBT and the combined study
arms. In this case, a small advantage for combined ther-
apy over CBT in the first 16 weeks of the study is
increased in the adjusted analysis, but falls to a negligible
difference at 52 weeks.
Secondary outcomes
Y-BOCS response rate
The number of full and partial responders was calculated,
defined, respectively, as 35 and 25% improvement in the
baseline Y-BOCS. The results showed a tendency for
either full or no response, with an advantage for combi-
nation treatment at week 16, and an equivalent advan-
tage for sertraline or combination treatment over CBT at
week 52 (Table 4).
MADRS
Although starting from a numerically lower baseline, the
MADRS scores for those in the CBT arm did not
improve and were numerically higher than baseline at
both week 16 and week 52. In contrast, MADRS scores
in the sertraline arm improved substantially over the first
8 weeks of treatment and remained low (< 10) between
the 8-week and the 52-week endpoints. In the combi-
nation arm, the magnitude of the improvement in the
MADRS was less than that for sertraline monotherapy,
and scores worsened after 16 weeks (Table 5).
At 16 weeks, the effect size of the difference between
the sertraline [mean MADRS= 8.1 (SD: 6.5)] and CBT
arms [mean MADRS= 14.9 (SD: 10.6)] was 0.75 (95%
CI: − 0.29 to 1.8). At week 52, the effect size of the
difference was 0.46 (95% CI: − 0.62 to 1.5). Similarly,
at week 16, the effect size of the difference between
the sertraline and the combination arms [mean
MADRS= 12.6 (SD: 9.3)] was 0.53 (95% CI: − 1.5 to
0.41), and, at week 52, it was 0.59 (95% CI: − 1.6 to 0.48).
CGI Severity
Over the 16-week treatment phase, CGI scores improved
similarly in the SSRI and combination arms, but not in
the CBT arm. After week 16, however, the SSRI and the
CBT arms showed further improvement, but the com-
bination group did not. At week 52, the mean CGIs
scores on sertraline, CBT and combined treatment were
respectively 2.2 (SD: 1.2), 2.9 (SD: 1.8) and 3.2 (SD: 1.7)
(Table 6).
CGI Improvement
Compared with baseline, at week 16, all three arms were on
average ‘minimally improved’ on the CGI Improvement,
with a numerical advantage for the combination arm. By
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week 52, further improvement was seen to the extent that
the SSRI and combination groups were ‘much improved’ to
a similar degree, whereas the CBT group was ‘minimally
improved’ (Table 6).
SDS
The SDS is a self-rated measure of impairment, scored in
three domains: family, social and working life, which
were totalled to provide a composite score. In the case of
missing data in one of the three domains, a pro rata score
for that domain was calculated. As some patients did not
work, the work domain was not scored, and, in these
cases, a pro rata score was estimated, wherein one of the
remaining domains was completed (Table 6).
Patients in all three groups showed a reduction in
symptom-related disability over the course of the study.
The maximum rate of improvement occurred in the first
16 weeks. At week 16, improvement was greatest in the
combination arm, next greatest in the SSRI arm and least
in the CBT arm, which remained the weakest interven-
tion until the final 52-week endpoint. After 16 weeks,
however, the advantage for combined treatment was lost,
and, at week 52, the greatest improvement was seen in
the SSRI arm.
Tolerability
A total of 288 AEs were recorded, of which 141 were
related to treatment. Three participants (one from each
arm) withdrew because of AEs. A total of 11 AEs were
judged as ‘severe’ (nine combined and two CBT), with
the rest being judged as ‘mild’ or ‘moderate’ severity.
Safety
Three serious AEs were reported: two (one CBT and one
SSRI) were not related to study treatment and involved
hospital admissions for termination of pregnancy. The
third was a suicide attempt, which was considered to be
possibly related to treatment with sertraline monotherapy.
Economic evaluation
Complete resource use and EQ-5D-3L data were available
(at baseline, 16 and 52 weeks) for 23 (46.9%) participants.Ta
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Table 4 Responder rates
CBT Sertraline Combined
16 Weeks
No response 8 (87.5) 4 (57) 5 (38)
>25% 0 (0) 0 (0) 2 (15)
>35% 1 (12.5) 3 (43) 6 (47)
52 Weeks
No response 4 (50) 2 (33) 3 (33)
>25% 1 (12.5) 0 (0) 0 (0)
>35% 3 (37.5) 4 (66) 6 (66)
Response calculated as >25% or >35% improvement in baseline total
Y-BOCS score.
CBT, cognitive-behavioural therapy; Y-BOCS, Yale Brown Obsessive
Compulsive Scale.
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The mean number of attended sertraline appointments per
participant allocated to the sertraline monotherapy group
was 4.67, compared with 5.56 for the sertraline plus CBT
group. In addition, the mean number of CBT-attended
sessions was 6.69 for those allocated to CBT monotherapy
(mean session length=101min/session) and 6.44 for
the sertraline plus CBT group (mean session length=
106min/session). As such, the mean annual intervention
costs were estimated to be lowest for sertraline mono-
therapy, followed by CBT monotherapy and sertraline plus
CBT. These intervention costs also outweighed other
NHS and PSS costs, wherein it is noticeable that, aside
from health professional contacts, very few other health
care services were used, and no professional carer input was
reported (Table 7). Over 52 weeks, the mean EQ-5D-3L
scores were estimated to increase for both the sertraline
monotherapy and the sertraline plus CBT, but there was a
slight fall for the CBT monotherapy group (0.189, 0.205
and −0.016, respectively).
On the basis of the regression analyses, when compared with
sertraline monotherapy, mean costs were £1328.57 (95% CI:
£555.39–2101.76) higher for the CBTmonotherapy arm and
£2175.70 (95% CI: £1385.13–2966.26) higher for the com-
bined arm. The mean QALY scores for sertraline mono-
therapy were 0.1823 (95% CI: 0.0447–0.3199), greater than
that of CBT monotherapy, and 0.1135 (95% CI: −0.0290 to
0.2560), greater than that of the combined arm. As such,
sertraline monotherapy was deemed dominant and cost-
effective, as it was estimated to be both less costly and more
effective than both other options. In addition, according to
the cost-effectiveness acceptability curve, at a threshold
value of £20 000/QALY, there was estimated to be a 5.3%
chance of making the wrong decision by choosing sertraline
monotherapy.
Discussion
Several interventions are available for treating OCD. Few
studies, however, have compared the relative effective-
ness of these interventions in a single analysis. In addi-
tion, given the chronic relapsing nature of OCD, there
has been insufficient study of the longer-term treatment
outcomes under controlled conditions.
To this end, Skapinakis et al. (2016c) recently performed
a systematic review and network meta-analysis, compar-
ing all available treatments for adults with OCD, using
both direct and indirect data. Fifty-four trials (6652 par-
ticipants) were included in the network meta-analysis. A
shortage of studies comparing active psychological ther-
apy with psychological placebo was noted. The results
showed that cognitive-behavioural forms of psychother-
apy as well as clomipramine and SSRI (as a class) pro-
duced greater improvement in clinical ratings than did
pill-placebo therapy. Psychotherapy interventions were
reported to be associated with a greater effect than
medication, but it was also noted that, in most psy-
chotherapy trials, patients who were taking stable dosesTa
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Table 6 CGI Severity, CGI Improvement and Sheehan Disability Scale scores on CBT, sertraline or combined treatment
Study arm Difference between arms
All CBT Sertraline Combined CBT vs. sertraline CBT vs. combined Sertraline vs. combined CBT vs. sertraline CBT vs. combined Sertraline vs. combined
Baseline 48 16 14 18 – – – – – –
CGI Severity 4.4 (0.96) 4.2 (1.0) 4.4 (0.85) 4.4 (0.98) – – – – – –
CGI Improvement – – – – – – – – – –
SDS 18.0 (7.0) 16.3 (6.8) 18.5 (8.3) 19.1 (6.3) – – – – – –
Week 8 35 12 9 14 – – – – – –
CGI Severity 4.1 (1.2) 4.3 (1.2) 3.7 (1.2) 4.1 (1.2) 0.67 (−0.47 to 1.8) 026 (−0.72 to 1.2) 0.4 (−0.67 to 1.5) 0.6 (−0.3 to 1.6) 0.6 (−0.4 to 1.5) −0.1 (−0.8 to 0.6)
CGI Improvement 3.4 (1.1) 3.6 (1.4) 3.2 (0.8) 3.4 (1.1) 0.4 (−0.7 to 1.5) 0.2 (−0.8 to 1.2) −0.1 (−1.0 to 0.7) – – –
SDS 12.8 (8.0) 13.5 (7.7) 11.8 (7.4) 13.1 (9.0) 1.7 (−5.7 to 9.0) 0.34 (−6.9 to 7.6) 1.3 (−6.1 to 8.8) 2.4 (−3.7 to 8.5) 3.7 (−1.9 to 9.3) 1.3 (−4.7 to 7.3)
Week 16 29 9 7 13 – – – – – –
CGI Severity 3.7 (1.6) 4.3 (1.0) 3.4 (2.2) 3.3 (1.4) 0.90 (−0.86 to 2.7) 1.0 (−0.13 to 2.2) −0.12 (−1.8 to 1.6) 0.63 (−7 to 2.0) 1.1 (0.2 to 1.9) 0.45 (−0.9 to 1.8)
CGI Improvement 3.0 (1.3) 3.6 (1.2) 3.1 (1.6) 2.5 (1.1) 0.4 (−1.1 to 1.9) 1.1 (0.1−2.1) 0.7 (−05 to 1.9) 0.01 (−1.2 to 1.2) 0.77 (−0.5 to 2.0) 0.76 (−0.4 to 1.9)
SDS 11.7 (9.0) 13.8 (8.3) 13.5 (9.9) 9.3 (8.9) 0.33 (−9.4 to 10.1) 4.6 (−3.3 to 12.4) 4.2 (−4.9 to 13.4) 0.81 (−5.2 to 6.8) 6.4 (1.2 to 11.6) 5.6 (−1.0 to 12.1)
Week 32 23 9 6 8 – – – – – –
CGI Severity 3.4 (1.5) 3.8 (1.1) 2.8 (1.7) 3.5 (1.9) 0.94 (−0.62 to 2.5) 0.28 (−1.3 to 1.8) 0.67 (−1.5 to 2.8) 0.4 (−0.8 to 1.7) 0.3 (−1.1 to 1.7) −0.2 (−1.7 to 0.5)
CGI Improvement 2.7 (1.5) 2.9 (0.8) 1.8 (1.2) 3.25 (2.0) 1.1 (−0.03 to 2.13) −0.4 (−1.9 to 1.2) −1.4 (−3.4 to 0.6) 0.5 (−0.8 to 1.7) −0.8 (−2.3 to 0.7) −1.3 (−3.0 to 0.4)
SDS 8.7 (8.8) 7.9 (5.8) 7.9 (11.3) 10.1 (10.2) −0.04 (−10.1 to 10.0) −2.3 (−11.2 to 6.7) −2.2 (−14.8 to 10.4) 0.4 (−7.7 to 8.5) −0.6 (−5.8 to 4.6) 1.0 (−9.4 to 7.4)
Week 52 23 8 6 9 – – – – – –
CGI Severity 2.8 (1.6) 2.9 (1.8) 2.2 (1.2) 3.2 (1.7) 0.71 (−1.1 to 2.6) −0.34 (−2.2 to 3.9) 1.1 (−0.69 to 2.8) 0.11 (−1.3 to 1.5) −0.47 (−2.1 to 1.1) −0.57 (−1.7 to 0.5)
CGI Improvement 2.3 (1.5) 2.6 (2.1) 2.2 (1.5) 2.1 (1.4) 0.4 (−1.6 to 2.4) 0.5 (−1.4 to 2.3) 0.06 (−1.3 to 1.5) −0.08 (−1.5 to 1.4) 0.12 (−1.5 to 1.7) 0.20 (−1.1 to 1.5)
SDS 9.3 (10.1) 9.8 (11.2) 8.1 (10.7) 9.7 (9.7) 1.7 (−11.2 to 14.7) 0.1 (−10.7 to 10.9) −1.6 (13.2–9.9) 1.2 (−0.76 to 10.1) 1.0 (−0.6 to 8.0) 0.23 (−8.5 to 8.0)
On the left hand side of the table, the numbers of randomized patients completing each rating point of the study are listed in the row below the mean total rating scale score (SD). The mean between-arm differences in scores (CI)
are listed in the middle columns, and the ITT analysis is presented on the right hand side.
CBT, cognitive-behavioural therapy; CI, confidence interval; ITT, intention-to-treat; SDS, Sheehan Disability Scale.
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of antidepressants were not excluded from the psy-
chotherapy arms. Thus, there was considerable uncer-
tainty about relative effectiveness. The analysis
concluded that the combination of behavioural forms of
psychotherapy with medications is probably more effec-
tive than either monotherapy, at least in the management
of severe OCD, and that pragmatic trials with improved
research design are needed to establish the differential
efficacy between psychotherapies and medications with
greater certainty.
The existing uncertainty is of major relevance for health
service planning, as NICE guidelines currently recom-
mend either CBT or SSRI monotherapy as first-line
approaches, reserving combination treatment for patients
with more severe or resistant OCD (National Institute for
Health and Care Excellence, 2006). Moreover, in countries
such as the UK, CBT is commonly provided for a range of
psychiatric disorders including OCD, being delivered in
nonmedical psychological therapy service settings, such as
the UK Improving Access to Psychological Therapies
programme (https://www.england.nhs.uk/mental-health/adults/
iapt/ ), wherein medicines management is not always
available.
The findings of this feasibility study underline this
uncertainty, thus emphasizing the need for a definitive
study, and also suggest that running such a study is likely
to be feasible and acceptable to patients.
Feasibility
Recruitment was acceptable across the study centres,
with secondary mental healthcare services acting as the
principal referral route. Retention to week 8 was also
acceptable across all the study arms. Although retention
in the combined arm remained good to week 16, a size-
able number of withdrawals occurred after 8 weeks in
both the monotherapy groups, suggesting a possible
advantage in terms of retention for combined treatment,
at least in the acute phase. To maximize the number of
evaluable cases, factoring in the unplanned delays related
to starting CBT, future studies may aim for a slightly
earlier primary endpoint, around 12 weeks. After
16 weeks, fewer patients discontinued, and the majority
of patients who had reached week 16 remained in the
study until the 52-week endpoint, suggesting that long-
term follow-up is feasible for those patients reaching the
end of acute-phase treatment.
Study treatment was generally well tolerated and
adhered to by the majority of patients. However, four
patients randomized to receive sertraline either reduced
or stopped it, while another four not randomized to ser-
traline procured an SSRI prescription from their GP.
When questioned, several patients explained that they
had found randomization difficult.
Eleven of a total of 288 AEs were considered to be
‘severe’. One patient receiving sertraline attempted sui-
cide, emphasizing the importance of caution in the
assessment of suicide risk in OCD patients. No specific
association has so far been reported in the scientific lit-
erature between the use of SSRI and suicidal acts in
adults with OCD. However, an observational cohort
study of patients with depression (Coupland et al., 2015)
reported increased rates of suicidal behaviour in the first
28 days of starting and stopping antidepressants, high-
lighting the need for careful monitoring of patients
receiving SSRI during these periods.
Effectiveness
As the number of patients completing 16 weeks fell short
of the study power set in the protocol, the findings are
subject to type I error, and we cannot be confident that the
Table 7 Mean total costs per participant (complete case, estimated annual mean cost per patient)
Mean total cost per participant Sertraline monotherapy (n=6) CBT monotherapy (n=8) CBT+ sertraline (n=9)
Sertraline
Prescribed medication £48.95 NA £38.64
Appointments and supervision £679.29 NA £626.29
Total sertraline costs £728.24 NA £664.93
CBT
Therapist sessions NA £1309.21 £1319.85
Training and Supervision NA £580.71 £580.68
Total CBT intervention cost NA £1889.92 £1900.53
Baseline Week 16 Week 52 Baseline Week 16 Week 52 Baseline Week 16 Week 52
Healthcare professional contacts £371.38 £118.51 £250.05 £164.23 £207.81 £646.86 £456.09 £190.23 £583.43
Hospital admissions £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00
A&E visits £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £22.41 £14.00
Day case procedure/outpatient visits £0.00 £66.34 £149.26 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00
Help from professional career £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.00
Total other NHS and PSS costs £371.38 £184.85 £399.31 £164.23 £207.81 £646.86 £456.09 £212.64 £597.43
Overall annual NHS and PSS costa £1312.40 – – – £2744.59 – £3375.54 – –
A&E, accident and emergency; CBT, cognitive-behavioural therapy; NA, not available; NHS, National Healthcare Services; PSS, personal social services.
aExcluding resource use at baseline; baseline incorporates resource use from the previous 4 months after randomization; week 16 incorporates the 16-week post-
randomization period; week 52 incorporates the final 36 weeks of annual follow-up after the randomization period.
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observed effect is reliable. Therefore, caution is required
when interpreting the study outcomes. Notwithstanding,
CBT fell considerably short of SSRI in terms of clinical and
cost-effectiveness on the observed case analyses, empha-
sizing the persisting need for a definitive study. On the
primary Y-BOCS analysis, at the primary 16-week end-
point, patients receiving CBT were responding less well
than those receiving sertraline (Cohen’s d= 0.27) or ser-
traline in combination with CBT (Cohen’s d= 0.39), sug-
gesting that the combined treatment arm may offer the
most clinically effective treatment, especially over CBT
monotherapy. These findings align with those from two
small historic placebo-controlled studies in adults with
OCD, one published by Hohagen et al. (1998), in which
SSRI combined with multimodal behaviour therapy out-
performed the psychological therapy given alone on a
number of clinical outcomes measures including obsessions
and depression, and one published by Cottraux et al.
(1993), in which fluvoxamine and exposure therapy were
synergistic, with an advantage for combined treatment over
exposure therapy on rituals at week 8 and on depression at
week 24.
If substantiated in a larger trial, our finding of superior
effectiveness for sertraline, either in combination with
CBT or as a monotherapy, would cast question on the
existing evidence-based treatment guidelines (National
Institute for Health and Care Excellence, 2006) that tend
to recommend CBT or SSRI monotherapy as equivalent
first-line treatments. Moreover, the finding that combi-
nation treatment may be the most efficacious in this
study sample, at least in the short term (≤ 16 weeks),
would suggest that combination treatment should not
necessarily be reserved for the most severe and
treatment-resistant patients.
Beyond week 16, falling retention across all groups made
interpretation exceedingly difficult. However, the advan-
tages of combination therapy were not sustained.
Sertraline monotherapy showed the greatest improvement
in the Y-BOCS at week 32 and week 52, outperforming
both CBT monotherapy with a large effect size (Cohen’s
d= 0.57 and 0.56, respectively) and also outperforming
combination treatment (Cohen’s d=0.49 and 0.44,
respectively).
The failure of combined treatment to show a sustained
advantage beyond 16 weeks is, on the face of it, difficult
to explain. The gains seen for CBT monotherapy after
16 weeks were slight, but those for SSRI monotherapy
were more robust, suggesting that combination with CBT
may somehow interfere with the effect of SSRI treat-
ment. Of note, the mean prescribed sertraline dose was
rather low overall, considering 200 mg/day is accepted as
the optimal dose, which may have reduced efficacy in
both the sertraline monotherapy and combined treatment
arms. However, this was more noticeable in the com-
bined arm, suggesting patients receiving CBT may have
experienced even more difficulties in taking sertraline at
optimized doses. This could provide an explanation as
to why they failed to improve to the same extent as their
monotherapy counterparts. In the combination arm,
patients and their clinicians may have biased the focus of
treatment towards the adjunctive CBT and held back from
taking the maximum sertraline dose. The possibility that a
negative interaction exists between receiving CBT and
medication should be investigated in more depth, as this
would have important treatment implications. Perhaps also
some of the gains associated with the combination arm
depended upon nonspecific therapist effects that were
missed after 16 weeks, when regular contact with the CBT
therapist came to an end. Clarification of these factors
should be pursued through quantitative and qualitative
analysis in the substantive study.
The secondary clinical outcomes largely aligned with the
Y-BOCS data, providing a degree of convergent validity
to the findings. Specifically, changes in the clinical global
severity and improvement scores and the SDS largely
mirrored the Y-BOCS data, at least up to week 16, with
numerical advantages seen for the combined treatment
and SSRI arms over CBT. In the case of the SDS, after
16 weeks, the advantages of combined treatment waned,
and, by week 52, sertraline showed the greatest
improvement and CBT the least.
Sertraline monotherapy produced the most beneficial
effect on depressive symptoms, with the mean baseline
MADRS improving by 50% as early as 8 weeks of
treatment. In contrast, CBT was associated with no
improvement in depressive symptoms: mean MADRS
scores at both endpoints were numerically higher than at
baseline. This finding runs contrary to a large meta-
analysis study of anxiety disorders and OCD, which
found that CBT significantly reduced depression in
patients with OCD (Hofmann and Smits, 2008). Perhaps
by adhering strictly to the exposure and response pre-
vention model, patients receiving CBT experienced
greater levels of distress that manifested as increased
MADRS scores. This may also explain the relatively
reduced ‘antidepressant’ effect when sertraline was
combined with CBT, compared with sertraline
monotherapy.
Health economic analysis
Despite the falling numbers and relatively low response
rates (49%), a preliminary health economic analysis was
possible. Sertraline monotherapy was estimated to be
associated with both a higher mean QALY gain and lower
mean costs, when compared with CBT monotherapy and
sertraline+CBT. These cost-effectiveness results had
associated uncertainty and should again be treated with
caution due to the relatively small sample size. In addi-
tion, they were based on a complete-case approach, and
such individuals may not be representative of all parti-
cipants. However, we have conducted sensitivity
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analyses (results available from authors), including mul-
tiple imputations (Faria et al., 2014), to account for
missing cost and outcome data, and, in each case, ser-
traline monotherapy was estimated to be cost-effective,
compared with the other two treatment options.
We are aware of two previous publications (National
Collaborating Centre for Mental Health, 2006;
Skapinakis et al., 2016b) looking at the cost-effectiveness
of CBT in OCD patients compared with SSRIs (at a class
level including sertraline) and CBT and SSRIs com-
bined. One (Skapinakis et al., 2016b) estimated that that
SSRIs were more cost-effective, whereas the other
(National Collaborating Centre for Mental Health, 2006)
estimated that the combined option was the most cost-
effective.
However, both were model-based studies based on a
number of assumptions, some of which, for example,
therapy frequency and session length, were not always
explicitly stated. Accordingly, explaining the reasons for
the differing results is not straight forward.
In this study, it was notable that total other NHS and PSS
costs were outweighed by the intervention costs in all
three groups, and that, within this cost category, health
professional contacts were by far the main cost driver.
Accordingly, resource items such as professional carer
time and accident and emergency visits seem unlikely to
have a notable influence in any future study, and there is
an argument that these need not be measured, as it
would reduce patient burden. In turn, this may improve
response rates, which were lower than expected, possibly
due to the requirement for in-person follow-up. In
addition, our study followed-up patients under controlled
conditions for 12 months only.
Considering the high relapse rates seen in patients
receiving treatment for OCD over 5 years (Eisen et al.,
2013), a longer-term follow-up period may be needed to
thoroughly review the cost-effectiveness of treatment for
this chronic debilitating disorder.
Advantages and limitations
The advantages of this study are the randomized design,
blinded raters, the exclusion of concomitant anti-
depressants, the ITT and observed case analysis, and the
use of accepted efficacy scales and pharmacoeconomic
assessments. The application of robust methodology is
important in a field where less careful methodology is
unfortunately common. Limitations include the low
numbers of participants, high dropout rates, low dosage
of sertraline and the use of some assumptions to calculate
the duration of healthcare contact in the different groups.
Observed case analysis is sensitive to the effect of
treatment in those participants who are known to be
taking it. Although this form of analysis is useful for
feasibility studies, it is likely to overestimate the true
effect size, and therefore cannot be considered definitive,
as the analysis is unable to take account of the effect of
treatment on those participants who failed to undergo
routine evaluation. In this study, the findings of super-
iority for SSRI on the Y-BOCS were not substantially
changed by the ITT analysis. At 16 weeks, the effect size
in favour of sertraline, or combined therapy over CBT,
is larger than for the observed cases, but, by 32 weeks,
the pattern is very similar to the observed cases.
Nevertheless, caution is required in interpreting our
observed case results, given the lack of study power, and
argues in favour of performing a large, definitive study.
Conclusion
Recruitment was feasible across the three study arms in
three centres, and the study procedures were acceptable
to the majority of patients. Retention was acceptable
across the three study arms up to week 8, and in the
combined arm up to week 16. To maximize the number
of evaluable cases, future studies may aim for a primary
endpoint around 12 weeks.
Longer-term participant retention was adequate, with the
majority of those who had reached week 16 remaining in
the study until the 52-week endpoint, suggesting that
long-term follow-up is feasible for those patients reaching
the end of acute-phase treatment.
At weeks 8 and 16, sertraline-treated patients responded
better than those receiving CBT in the observed case
analyses. The combined arm appeared to offer the most
clinically effective treatment (especially over CBT) in
the acute treatment phase. Beyond week 16, falling
retention made interpretation difficult, but several ana-
lyses including a preliminary health economic analysis
suggested that there were ongoing advantages for
receiving sertraline relative to CBT.
Implications
Were these findings to be substantiated in a more defi-
nitive study, that is, if sertraline monotherapy were to be
associated with greater sustained efficacy and lower costs
than usual care with CBT, there would be the potential
for changes to existing treatment guidelines with result-
ing large cost savings to the NHS. Further research
would, therefore, be of value: our study confirms that a
definitive study can and should be conducted.
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